The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC).
M. D. Walsh
No relevant relationships to disclose
H. Giovinazzo
No relevant relationships to disclose
A. Sheikh
No relevant relationships to disclose
M. Ivanovic
No relevant relationships to disclose
A. B. Whitlow
No relevant relationships to disclose
S. E. Newman
No relevant relationships to disclose
N. M. La-Beck
No relevant relationships to disclose
R. J. Kowalsky
No relevant relationships to disclose
B. A. Zamboni
No relevant relationships to disclose
D. L. Clarke-Pearson
No relevant relationships to disclose
W. R. Brewster
No relevant relationships to disclose
L. Van Le
No relevant relationships to disclose
V. L. Bae-Jump
No relevant relationships to disclose
P. A. Gehrig
No relevant relationships to disclose
W. Zamboni
No relevant relationships to disclose